Phase i study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702)

Rikiya Onimaru, Hiroki Shirato, Taro Shibata, Masahiro Hiraoka, Satoshi Ishikura, Katsuyuki Karasawa, Yukinori Matsuo, Masaki Kokubo, Yoshiyuki Shioyama, Haruo Matsushita, Yoshinori Ito, Hiroshi Onishi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose To estimate the maximum tolerated dose (MTD) and to determine the recommended dose (RD) of stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinoma (NSCLC) with target volume (PTV) < 100 cc. Materials and methods The continual reassessment method (CRM) was used to determine the dose level that patients should be assigned to and to estimate the MTD. Dose limiting toxicity (DLT) was grade 3 radiation pneumonitis (RP) within 180 days after the start of SBRT, grade 2 RP was used as a surrogate DLT. The RD was equal to the MTD. The dose was prescribed at D 95 of the PTV. Results Fifteen patients were accrued. Only 1 experienced grade 2 RP at 60 Gy in 4 fractions. It was difficult to fulfill the dose constraints at 60 Gy in 4 fractions, and the maximum dose level assigned by CRM was changed to 55 Gy in 4 fractions. The lower limit of 95% of the credible interval exceeded the adjacent level, and the RD was determined as 55 Gy in 4 fractions. Conclusions The RD of SBRT for peripheral T2N0M0 NSCLC with PTV < 100 cc was determined to be 55 Gy in 4 fractions.

Original languageEnglish
Pages (from-to)276-280
Number of pages5
JournalRadiotherapy and Oncology
Volume116
Issue number2
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Radiation Pneumonitis
Maximum Tolerated Dose
Non-Small Cell Lung Carcinoma
Radiotherapy
Carcinoma

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Phase i study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702). / Onimaru, Rikiya; Shirato, Hiroki; Shibata, Taro; Hiraoka, Masahiro; Ishikura, Satoshi; Karasawa, Katsuyuki; Matsuo, Yukinori; Kokubo, Masaki; Shioyama, Yoshiyuki; Matsushita, Haruo; Ito, Yoshinori; Onishi, Hiroshi.

In: Radiotherapy and Oncology, Vol. 116, No. 2, 01.01.2015, p. 276-280.

Research output: Contribution to journalArticle

Onimaru, R, Shirato, H, Shibata, T, Hiraoka, M, Ishikura, S, Karasawa, K, Matsuo, Y, Kokubo, M, Shioyama, Y, Matsushita, H, Ito, Y & Onishi, H 2015, 'Phase i study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702)', Radiotherapy and Oncology, vol. 116, no. 2, pp. 276-280. https://doi.org/10.1016/j.radonc.2015.07.008
Onimaru, Rikiya ; Shirato, Hiroki ; Shibata, Taro ; Hiraoka, Masahiro ; Ishikura, Satoshi ; Karasawa, Katsuyuki ; Matsuo, Yukinori ; Kokubo, Masaki ; Shioyama, Yoshiyuki ; Matsushita, Haruo ; Ito, Yoshinori ; Onishi, Hiroshi. / Phase i study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702). In: Radiotherapy and Oncology. 2015 ; Vol. 116, No. 2. pp. 276-280.
@article{8e905a5d596d488b9e975d7352515f7a,
title = "Phase i study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702)",
abstract = "Purpose To estimate the maximum tolerated dose (MTD) and to determine the recommended dose (RD) of stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinoma (NSCLC) with target volume (PTV) < 100 cc. Materials and methods The continual reassessment method (CRM) was used to determine the dose level that patients should be assigned to and to estimate the MTD. Dose limiting toxicity (DLT) was grade 3 radiation pneumonitis (RP) within 180 days after the start of SBRT, grade 2 RP was used as a surrogate DLT. The RD was equal to the MTD. The dose was prescribed at D 95 of the PTV. Results Fifteen patients were accrued. Only 1 experienced grade 2 RP at 60 Gy in 4 fractions. It was difficult to fulfill the dose constraints at 60 Gy in 4 fractions, and the maximum dose level assigned by CRM was changed to 55 Gy in 4 fractions. The lower limit of 95{\%} of the credible interval exceeded the adjacent level, and the RD was determined as 55 Gy in 4 fractions. Conclusions The RD of SBRT for peripheral T2N0M0 NSCLC with PTV < 100 cc was determined to be 55 Gy in 4 fractions.",
author = "Rikiya Onimaru and Hiroki Shirato and Taro Shibata and Masahiro Hiraoka and Satoshi Ishikura and Katsuyuki Karasawa and Yukinori Matsuo and Masaki Kokubo and Yoshiyuki Shioyama and Haruo Matsushita and Yoshinori Ito and Hiroshi Onishi",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.radonc.2015.07.008",
language = "English",
volume = "116",
pages = "276--280",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Phase i study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702)

AU - Onimaru, Rikiya

AU - Shirato, Hiroki

AU - Shibata, Taro

AU - Hiraoka, Masahiro

AU - Ishikura, Satoshi

AU - Karasawa, Katsuyuki

AU - Matsuo, Yukinori

AU - Kokubo, Masaki

AU - Shioyama, Yoshiyuki

AU - Matsushita, Haruo

AU - Ito, Yoshinori

AU - Onishi, Hiroshi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose To estimate the maximum tolerated dose (MTD) and to determine the recommended dose (RD) of stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinoma (NSCLC) with target volume (PTV) < 100 cc. Materials and methods The continual reassessment method (CRM) was used to determine the dose level that patients should be assigned to and to estimate the MTD. Dose limiting toxicity (DLT) was grade 3 radiation pneumonitis (RP) within 180 days after the start of SBRT, grade 2 RP was used as a surrogate DLT. The RD was equal to the MTD. The dose was prescribed at D 95 of the PTV. Results Fifteen patients were accrued. Only 1 experienced grade 2 RP at 60 Gy in 4 fractions. It was difficult to fulfill the dose constraints at 60 Gy in 4 fractions, and the maximum dose level assigned by CRM was changed to 55 Gy in 4 fractions. The lower limit of 95% of the credible interval exceeded the adjacent level, and the RD was determined as 55 Gy in 4 fractions. Conclusions The RD of SBRT for peripheral T2N0M0 NSCLC with PTV < 100 cc was determined to be 55 Gy in 4 fractions.

AB - Purpose To estimate the maximum tolerated dose (MTD) and to determine the recommended dose (RD) of stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinoma (NSCLC) with target volume (PTV) < 100 cc. Materials and methods The continual reassessment method (CRM) was used to determine the dose level that patients should be assigned to and to estimate the MTD. Dose limiting toxicity (DLT) was grade 3 radiation pneumonitis (RP) within 180 days after the start of SBRT, grade 2 RP was used as a surrogate DLT. The RD was equal to the MTD. The dose was prescribed at D 95 of the PTV. Results Fifteen patients were accrued. Only 1 experienced grade 2 RP at 60 Gy in 4 fractions. It was difficult to fulfill the dose constraints at 60 Gy in 4 fractions, and the maximum dose level assigned by CRM was changed to 55 Gy in 4 fractions. The lower limit of 95% of the credible interval exceeded the adjacent level, and the RD was determined as 55 Gy in 4 fractions. Conclusions The RD of SBRT for peripheral T2N0M0 NSCLC with PTV < 100 cc was determined to be 55 Gy in 4 fractions.

UR - http://www.scopus.com/inward/record.url?scp=84953839958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953839958&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2015.07.008

DO - 10.1016/j.radonc.2015.07.008

M3 - Article

VL - 116

SP - 276

EP - 280

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 2

ER -